ARRJF:OTC-Arjo AB (publ) (USD)

COMMON STOCK | Medical Distribution | OTC

Last Closing Price

USD 7.38

Change

0.00 (0.00)%

Market Cap

USD 2.97B

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. The company offers products and solutions for patient handling, hygiene, disinfection, medical beds, treatment and prevention of pressure injuries and leg ulcers, prevention of deep vein thrombosis, treatment of edema, and for obstetric and cardiac diagnostics. It also provides dementia and bariatric room assessment solutions, as well as clinical consulting, maintenance, and equipment rental and financing solutions. The company serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmö, Sweden.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SHTDY Sinopharm Group Co., Ltd

-0.76 (-5.02%)

USD9.50B 7.97 0.54
SHTDF Sinopharm Group Co., Ltd

-0.10 (-3.39%)

USD8.99B 7.76 0.54
SHPMF Shanghai Pharmaceuticals Holdi..

N/A

USD8.23B 7.05 1.03
SHPMY Shanghai Pharmaceuticals Holdi..

N/A

USD8.08B 6.92 1.03
CAKFF McKesson Europe AG

N/A

USD6.22B 25.10 28.04
CAKFY McKesson Europe AG

N/A

USD6.06B 25.00 17.47
MAHLY MediPal Holdings Corporation

N/A

USD4.15B 20.32 0.03
CQCQ MakingORG, Inc

N/A

USD0.12B N/A N/A
EXHI Exlites Holdings International..

N/A

USD0.02B N/A N/A
FZMD Fuse Medical, Inc

N/A

USD0.01B 25.00 507.54

ETFs Containing ARRJF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Distribution)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.03% 60% D- 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.03% 53% F 55% F
Trailing 12 Months  
Capital Gain 29.47% 73% C 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.47% 67% D+ 40% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 27.13% 88% B+ 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.13% 88% B+ 63% D
Risk Return Profile  
Volatility (Standard Deviation) 22.51% 50% F 76% C
Risk Adjusted Return 120.56% 100% A+ 99% A+
Market Capitalization 2.97B 56% F 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Distribution)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 136.67 9% F 6% F
Price/Book Ratio 2.67 20% F 41% F
Price / Cash Flow Ratio 1.31 31% F 38% F
EV/EBITDA 1.90 40% F 61% D-
Management Effectiveness  
Return on Equity 9.31% 64% D 68% D+
Return on Invested Capital 9.08% 56% F 71% C-
Return on Assets 4.32% 87% B+ 81% B-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.05 81% B- 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector